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ABSTRACT 
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To relate exposure to adverse health effects, it is necessary to know where particles in the 
submicron range deposit in the respiratory tract. The possibly higher vulnerability of children 
requires specific inhalation studies. However, radio-aerosol deposition experiments involving 
children are rare because of ethical restrictions related to radiation exposure. Thus, an in 
vivo study was conducted using three baboons as a child respiratory tract model to assess 
regional deposition patterns (thoracic region vs. extrathoracic region) of radioactive 
polydisperse aerosols ([d16-d84], equal to [0.15 µm–0.5 µm], [0.25 µm–1 µm], or [1 µm–9 
µm]). Results clearly demonstrated that aerosol deposition within the thoracic region and the 
extrathoraic region varied substantially according to particle size. High deposition in the 
extrathoracic region was observed for the [1 µm–9 µm] aerosol (72% ± 17%). The [0.15 µm–
0.5 µm] aerosol was associated almost exclusively with thoracic region deposition (84% ± 
4%). Airborne particles in the range of [0.25 µm–1 µm] showed an intermediate deposition 
pattern, with 49% ± 8% in the extrathoracic region and 51% ± 8% in the thoracic region. 
Finally, comparison of baboon and human inhalation experiments for the [1 µm–9 µm] 
aerosol showed similar regional deposition, leading to the conclusion that regional deposition 
is species-independent for this airborne particle sizes.  
KEY WORDS  
airborne particles, deposition pattern, respiratory tract, child, baboon, scintigraphy 
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INTRODUCTION  
 
The likelihood of the presence of primary nano-objects, i.e., manufactured structures 
such as nanofibers, nanoplates, and nanoparticles [1], in the air seems to be low. There are 
indications that the lifetime of primary airborne nanoparticles (considered to be <100 nm) is 
limited by a rapid coagulation process. Larger airborne aggregates (or agglomerates) can be 
formed. Some authors have suggested the attachment of the nanoparticles to larger 
background particles and the mutual coagulation of the nano-sized aerosols [2,3]. 
Concentration dependency was also observed: the higher the concentrations, the more rapid 
the coagulation. In real-world workplace conditions, the lifetime of primary airborne 
nanoparticles is limited, and it would be more likely for individuals to be exposed to 
nanoparticle agglomerate aerosol. Thus, some authors have suggested that occupational 
exposure to the release of nano-size particles in the air might be mimicked by a submicronic 
aerosol with two populations, one of approximately 200 to 600 nm and one of approximately 
2000 to 3000 nm, which might imply that workers inhale aerosol submicron-size fractions 
rather than aerosol nano-size fractions [4]. 
 
To relate exposure to adverse health effects, it is crucial to assess the deposition 
pattern of inhaled particles in the respiratory tract. The identification of deposition sites is a 
major determinant of particle biopersistence, clearance from the respiratory tract, the dose 
pattern in tissues, and the resultant biological effects. Spaces like the extrathoracic airways 
show fast mucociliary clearance, with residence time in the range of hours to 1 day. Thus, 
the deposition of submicron-size nanoparticle agglomerates in this region may have less 
toxicological impact compared to alveolar deposition, with long clearance times in the range 
of days to months for poorly soluble particles. However, high alveolar deposition enables 
possible systemic translocation of primary nanoparticles [5].  
 
 4 
 
As a result, it would be relevant for risk assessment purposes to know the size of submicron-
size nanoparticles agglomerates in the 200-nm to 600-nm range that are preferentially 
deposited in the pulmonary alveolar spaces. The region of the respiratory tract affected by 
particle deposition largely depends on particle properties (e.g., micrometer-size vs. 
submicron-size particles), and also on anatomic and physiologic properties (e.g., adult vs. 
child respiratory tract model) [5,6]. Despite behavioral and physiological differences between 
adults and children, experimental investigations of the regional deposition pattern of inhaled 
particles within the respiratory tract have mainly focused on adults, with children typically 
addressed by mathematical modeling. Application of models of inhaled particle deposition is 
largely based on extrapolating anatomical and physiological data from young adults to match 
the changes observed during growth and aging [7]. For micrometer-size aerosol, the particle 
deposition models consistently predict greater tracheobronchial aerosol deposition and 
lesser pulmonary deposition for children than that calculated for adults [8]. Only 
approximately 50 studies that measure the respiratory tract deposition of particles smaller 
than 300 nm have been reported [9]. However, with age, there may be significant variations 
in species-specific particle deposition factors [10,11]. Thus, children may receive a greater 
internal dose of submicron nanoparticle agglomerates than do adults because of different 
airway architecture and greater ventilation rate per body weight or lung surface area [12]. 
Moreover, metabolic differences may result in different tissue burdens. This can lead to 
differences between children and adults regarding submicron-size nanoparticle agglomerate 
doses, elimination, and toxicity.  
 
This possibly higher vulnerability of children requires designing specific inhalation 
studies. In this context, baboons are generally considered to be the best animal model for 
extrapolating data regarding aerosol deposition in human airways [13,14]. A morphometric 
comparison of baboon airways with the respiratory tract geometry of a 2-year-old child 
suggests a functional interspecific relationship between the nasal structure, cross-sectional 
area, and tracheobronchial region [15,16]. The main objective of this article was to assess 
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doses of inhaled submicron-size aerosol in baboons (i.e., an animal model of the human 
child respiratory tract). Therefore, an in vivo study was conducted using three baboons to 
assess regional deposition patterns (thoracic [TH] region vs. extrathoracic [ET] region) of 
radioactive polydisperse aerosols ([d16-d84] equal to [0.15 µm–0.5 µm], [0.25 µm–1 µm], or 
[1 µm–9 µm]), which are quite well-representative of nanoparticle agglomerates observed in 
the case of airborne nanoparticle exposure [4]. 
 
MATERIALS AND METHODS 
 
Aerosol Generation and Characterization 
 
 The following commercial jet medical nebulizers were used to generate micrometric 
and submicrometric aerosols: Atomisor NL11 (DTF Medical, Saint-Etienne, France); modified 
Sidestream (Ref 12NEB400; Philips Respironics, Tangmere, England); and a Nanoneb (DTF 
Medical). Nebulizers were loaded with 2 mL diethylenetriamine pentaacetic acid (DTPA) 
solution (Pentacis; CIS Bio International, Gif-sur-yvette, France) containing 74 MBq 
technetium 99m (99mTc). Aerosols were generated by using an air tank (Air Liquide, Paris, 
France) with a flow rate of 8 L/min.  
 
Particle size distributions of the analyzed radioactive aerosols were determined by 
using a gamma camera (Ecam; Siemens) coupled to a specific electrical low-pressure 
impactor (ELPI; Dekati, Kangasala, Finland). The ELPI was specifically devoted to airborne 
nanoparticles. With this device, operated at an air flow rate of 10 L/min, particles are 
impacted depending on their inertia-related aerodynamic diameter at one of the 12 size 
fraction stages of the impactor (range, 10 µm–7 nm). To operate the ELPI at the specific flow 
rate, 2 L/min of dilution air (at controlled relative humidity) was added to the nebulizer flow 
rate. Before each measurement, the 12 ELPI impaction stages were cleared. The corona 
charger was turned off during experiments to avoid the artifact effect of particles charging 
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and electrical detection. Consequently, the particle distribution was characterized using the 
ELPI with the particles not being electrically charged. During aerosol measurements, each 
nebulizer was directly connected with the ELPI impactor system. The aerosol produced was 
then collected and sampled because the aerosolized particles are impacted at different 
stages according to their inertia related to their aerodynamic diameter. At the end of 
nebulization, defined as 1 minute after the beginning of the sputtering, the radioactivity from 
aerosol particles deposited in each size-specific stage was quantified by scintigraphy 
imaging. The ELPI directly measured the activity in the particle size distribution once the 
activity distribution with a median size was able to be described. Thus, the ELPI device 
allowed the measurement of the activity median aerodynamic diameter (AMAD); however, at 
the same time, it also permitted quantifying the total amount of radioactivity delivered by the 
nebulizer to calculate the emitted nebulizer fraction sum of the activity during the 12 stages 
and the human throat model inserted before the ELPI.  
In short, the emitted nebulizer fraction, the particle size distribution, the AMAD with 
geometric standard deviation (GSD), the fine particle (FP) fraction (including all particles with 
an aerodynamic diameter <2.5 µm), the ultrafine particle fraction (including all particles with 
an aerodynamic diameter <0.1 µm), and the [d16–d84] particle size range (where d16 and 
d84 are the particle diameters at the 16% and 84% size cut-offs of the cumulative 
distribution, respectively) were calculated from radioactivity deposited at each ELPI stage. 
Furthermore, raw current charges of airborne particles were also analyzed. Although all 
studied aerosols were exclusively composed of positively charged particles, the [1 µm–9 µm] 
aerosol presented higher raw current values.  
The ELPI measurement neglects any hygroscopic changes of the nebulizer droplets. 
However, the particle sizes measured by the ELPI are subject to possible size changes.  
 
Animals and Housing Conditions 
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In vivo experiments were performed with three healthy baboons (Papio anubis) 
weighing 10 to 14 kg (age, 6.3 ± 0.5 years). Animals were obtained from an official supplier 
(Station de primatologie de Rousset, Marseille, France). Animal accommodations were in 
accordance with the last European legislation (Directive 2010/63/UE). Baboons were housed 
as a social group in three stainless-steel mesh cages (2 × 2 × 2 m) that were maintained with 
the doors open. Temperature (22°C ± 2°C) and relative humidity (range, 30%–70%) of the 
room were measured, controlled, and recorded daily. An artificial lighting cycle of 12 hours 
(from 8:00 AM to 8:00 PM) was maintained. Each day, the animals were offered an expanded 
commercial primate diet (808000; SDS, St. Gratien, France).  
 No animals were killed during this study. Enrichment is widely believed to improve the 
psychological health of nonhuman primates. Attention to the psychological well-being of 
laboratory primates derives from ethical concerns for the welfare of creatures and from the 
need to ensure a healthy subject for research. Baboons were kept in a harmonious group 
with music playing from speakers and wildlife films shown on television (once per week) to 
allow social and environmental enrichment. Moreover, to address their arboreal nature, we 
provided laboratory baboons with access to a place to sit or climb above floor level. Their 
diets were also supplemented with fresh fruits. Their main drinking water was available ad 
libitum from automatic dispensers. Baboons have hands that resemble those of humans, and 
they can spend many minutes at a time manipulating their environment. To provide 
opportunities for manipulation, we provided baboons with cage toys that were regularly 
changed.  
In Vivo Experimental Design and Image Acquisition 
 
One of the main challenges for calibration and comparison of instruments for lung deposition 
experiments is the lack of a realistic common "standard" or "reference" method. A recent 
review of the measurement techniques for respiratory tract deposition of airborne 
nanoparticles recommended experimental procedures to minimize errors [9]. This study 
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takes into account some of these suggestions to limit biases attributable to measurement 
problems. The experimental protocol was conducted according to National Institutes of 
Health Guidelines for the Care and Use of Laboratory Animals and according to the approval 
of a local ethics board (protocol was recorded by the French National Committee of Ethical 
Reflection on Animal Experiments). Baboons were placed on a special chair under 
anesthesia via intramuscular injection of xylazine (1 mg/kg) and ketamine (5 mg/kg). The 
animals were sedated, but they were kept awake while aerosol was administered through a 
tight-fitting face mask (Ref 93815028; Temsega, France) specifically designed for baboons 
with a combination of oral and nasal inhalation routes. Each baboon inhaled an aerosol twice 
for each of the three different types of nebulizers selected for this study, resulting in six 
inhalations per nebulizer. The order of the nebulizers tested was randomized for each 
baboon. The nebulizer charge was controlled by counting the radioactivity in the syringe 
using a gamma counter (Capintec; France) before and after charging. The nebulizer was 
then connected to the face mask and to an expiratory filter to avoid air contamination. It was 
operated until 1 minute after the aerosol began to sputter. Immediately after aerosol delivery, 
the animals and the circuit components were scanned using a gamma camera (Ecam; 
Siemens). A 120-second posterior static view was acquired on a 128 × 128 matrix. The 
amount of 99mTc-DTPA deposited in the lungs was determined from the digitized images. 
This in vivo study was conducted under the approval of the ethics board at the Medicine 
University of Tours in France (file number 2010/20). Baboon tidal volume was measured with 
a pneumotach (Dyn R, Muret, France) in the three studied baboons (Table 1). Deposition in 
the ET and TH regions was expressed as a fraction of the inhaled aerosol amount, which is 
more relevant to ambient aerosol exposure estimation than using emitted nebulizer fraction. 
The inhaled aerosol fraction was estimated by dividing baboon minute ventilation (1.8 L/min) 
by nebulizer flow rate (8 L/min), neglecting the inhalability losses during the experiments. 
 
Image Analysis 
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 The strategy to assess regional deposited amounts of aerosol in the ET and the TH 
regions is a first step to differentiate the respiratory tract into different regions. The 
scintigraphic images of aerosol deposition in baboons were post-treated with a 9-point 
convolution mask filter to reduce background noise without loss of image information. The 
regions of interest were determined manually, delimiting two main regions, the TH region and 
the ET region [17]. Background noise was subtracted from measured counts of radioactivity 
within regions of interest. All images presented a good count rate, giving the data a relative 
accuracy of 3%. Furthermore, corrections for physical decay of 99mTc were made for all 
measurements. Tissue attenuation coefficients were also taken into account. Lung tissue 
attenuation correction factors were determined from lung perfusion imaging of each baboon 
using pertechnetate-macroaggregated albumin. Stomach tissue attenuation correction 
factors were determined from administration of 5 mL 99mTc-DTPA via a catheter directly into 
the stomach of each baboon. Head tissue attenuation correction factors were determined by 
placing a tube containing 5 mL 99mTc-DTPA in the mouth of each baboon. All images were 
recorded from the anterior view of the baboon.  
 
 
Statistical Analysis 
 
 Statistics were performed using GraphPad Prism Software version 5 (GraphPad, ). A 
Bonferroni multiple comparison test was used to compare the data generated (p < 0.05 was 
considered statistically significant). 
 
Ethics Approval 
 
 This study was approved by the local ethics board of Tours University (file number 
2010/20) and was recorded by the French National Committee of Ethical Reflection on 
Animal Experiments (CNREEA, under number CEEAVdL-19). 
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RESULTS 
 
Particle Size Distribution  
 
 Particle size distributions of the three polydisperse aerosols are shown in Figure 1 
and summarized in Table 2. Because the particle size distributions are broad and quite far 
from a monodisperse distribution, we chose to characterize the aerosol distribution by the 
means of the [d16–d84] particle size range. AMAD of 2.8 µm (GSD of 3.2; [d16–d84] = [1 
µm–9 µm]; Atomisor NL11), 550 nm (GSD of 2.1; [d16–d84] = [0.25 µm–1 µm]; modified 
Sidestream), and 230 nm (GSD of 1.6; [d16–d84] = [0.15 µm–0.5 µm]; Nanoneb) were 
obtained. Almost all particles produced by the [0.15 µm–0.5 µm] aerosol (98.6%) and the 
[0.25 µm–1 µm] aerosol (98.3%) were smaller than 2.5 µm, which corresponded to the FP 
that are likely to be deposited in the lungs [6,18]. In contrast, less than half of the [1 µm–9 
µm] aerosol (47%) was considered FP. All things considered, the [0.15 µm–0.5 µm] aerosol 
produced the larger amount of ultrafine particle fractions smaller than 0.1 µm (7.3%), almost 
four-times higher than the [0.25 µm–1 µm] aerosol and 20-times higher than the [1 µm–9 µm] 
aerosol (Table 2).  
 
 
 
In Vivo Regional Deposition: ET/TH Deposition Balance 
 
 In the submicron-size range studied, results demonstrated that the TH region 
deposition decreased as particle sizes increased (Figure 2). A huge deposition in the ET 
region was found for the [1 µm–9 µm] aerosol (72% ± 17% of the total aerosol fraction 
deposited), whereas the [0.15 µm–0.5 µm] aerosol showed the smallest ET region deposition 
(only 16% ± 4% of the total aerosol fraction deposited). As a result, aerosols with smaller 
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AMAD (i.e., 230 nm or [0.15 µm–0.5 µm]) were associated almost exclusively with thoracic 
deposition (84% ± 4% of the total aerosol fraction deposited). Finally, [0.25 µm–1 µm] 
aerosol with AMAD of 550 nm showed intermediate behavior, with 49% ± 8% of the total 
aerosol deposition in the ET region and 51% ± 8% in the TH region. Statistical analysis 
(summarized in Table 3) confirmed that particle size is the main factor influencing aerosol 
deposition in the ET and TH regions. Results exhibited three different patterns of aerosol 
deposition (i.e., three different ET/TH deposition balances) for the particle sizes studied (i.e., 
2.8 µm, 550 nm, and 230 nm). 
 
In Vivo Regional Distribution: Aerosol Deposited and Aerosol Exposure 
 
 The ET/TH deposition balance led to interesting data and was also useful for 
determining the mass of aerosol deposited as a function of the inhaled aerosol fraction (i.e., 
the amount of particles inhaled by the baboons) rather than the emitted aerosol fraction (i.e., 
the amount of particles delivered by the nebulizer in the atmosphere during aerosol 
exposure) (Table 4). For the [1 µm–9 µm] aerosol, we observed a five-fold higher emitted 
fraction (44.5% ± 1.5% vs. 9.3% ± 3%) compared with the [0.25 µm–1 µm] aerosol and a 10-
fold higher emitted fraction compared with the [0.15 µm–0.5 µm] aerosol (44.5% ± 1.5% vs. 
4.2% ± 1%). Thus, results for the deposited fractions can be expressed in terms of the 
percentage of the inhaled aerosol fraction (Figure 3). The results show a great impact of the 
particle size on the relative deposition efficiency. In fact, a higher total deposition fraction was 
obtained for the [0.25 µm–1 µm] aerosol, with 1.6-fold and 1.35-fold higher total deposition 
fractions than the [0.15 µm–0.5 µm] and [1 µm–9 µm] aerosols, respectively. We 
demonstrated that the fraction deposited in the ET region was statistically constant for [1 
µm–9 µm] or [0.25 µm–1 µm] aerosols (16.5% ± 7.1% and 15.3% ± 5.3%, respectively), 
whereas it significantly decreased for the [0.15 µm–0.5 µm] aerosol (3.3% ± 2.2%). As a 
result, the higher regional deposition fraction in the ET region was observed for the [1 µm–9 
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µm] and [0.25 µm–1 µm] aerosols, with five-fold higher deposition than the [0.15 µm–0.5 µm] 
aerosol. Moreover, the fraction deposited in the TH region was relatively low for the [1 µm–9 
µm] particles (5.8% ± 2.9%), but it significantly increased for the [0.25 µm–1 µm] and [0.15 
µm–0.5 µm] aerosols (14.7% ± 1.6% and 15.5% ± 7.1%, respectively). Therefore, the higher 
regional deposition fraction in the TH region was observed for the [0.15 µm–0.5 µm] and 
[0.25 µm–1 µm] aerosols, with a 2.5-fold higher deposition than the [1 µm–9 µm] aerosol. 
 
DISCUSSION  
 
Impact of Airborne Particle Size on the ET/TH Deposition Balance in Terms of the Total 
Aerosol Fraction Deposited  
 
Patterns of regional deposition of particles within airways remain a key experimental 
issue to successfully predict where pathological changes may occur or to estimate the 
possibility of translocation through the air–blood barrier. Numerous regional deposition data 
for humans were developed as a function of particle size as early as the 1960s, e.g., 
radiolabeled methacholine studies [19,20] and the numerous bolus studies examining 
regional deposition. However, many aerosol deposition experiments in humans and in 
laboratory animals have focused on the total deposited fraction [18,21–25]. This fraction can 
be measured by comparing particle concentrations in the inhaled and exhaled air, but 
regional involvement cannot be distinguished. Additionally, studies are generally devoted to 
the deposition pattern within adult respiratory tract models and focus on micrometer-size 
particle ranges. In vivo studies of the regional deposition of submicron-size particles in the 
respiratory tract are still scarce, and aerosol deposition studies involving infants and children 
are even more rare, with only a few experimental studies related to children relayed in the 
literature [26,27]. However, deposition is generally assessed by using inhalation of 
radiolabeled aerosols and gamma scintigraphy imaging, and this radiation exposure places 
ethical restrictions on performing such studies in children. 
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In this context, one of the main results obtained is the demonstration that regional 
aerosol deposition in a child respiratory tract model varies substantially according to the 
polydisperse aerosol features in the submicrometer-size particle range (Figure 2). We 
showed that the smallest AMAD aerosol (i.e., 230 nm or [0.15 µm–0.5 µm]) led to targeted 
deposition in the TH region. The high proportion of small particles contained in the [0.15 µm–
0.5 µm] airborne particles (86.6% ± 1.8% of particles <0.5 µm) (Table 2) may explain the 
targeted thoracic deposition and the low intersubject variability observed (Figure 2). The 
fraction of particles smaller than 0.5 µm appeared to be correlated with aerosol deposition in 
the TH region. The [0.15 µm–0.5 µm] aerosol showed a 1.8-fold higher amount of particles 
smaller than 0.5 µm compared with the [0.25 µm–1 µm] aerosol (86.6% ± 1.8% vs. 47.9% ± 
4.4%) (Table 2) and a 1.8-fold higher deposition in the TH region (84% ± 4% vs. 51% ± 8%) 
(Figure 2). Nevertheless, this correlation was nonlinear and not easily extrapolated to the [1 
µm–9 µm] aerosol (only 4.7% ± 0.6% of particles <0.5 µm but significant deposition in the TH 
deposition at 28% ± 17%). Additionally, particle deposition in the upper airways was mainly 
observed for particles with a median diameter of [1 µm–9 µm] (72% ± 17%). This 
experimental evidence was also supported by an in vivo study of pattern aerosol deposition 
[28].  
 
Nevertheless, the airborne particles delivered by nebulizers could present high 
polydispersity, and thus the different mechanisms of deposition (impaction, sedimentation, 
diffusion) could occur simultaneously for a polydisperse aerosol. As an example, even if the 
AMAD of the atomizer nebulizer is 2.8 µm, significant amounts of FP and ultrafine particle 
fractions are also present (Figure 1, Table 2). The [1 µm–9 µm] aerosol has a GSD of 3.2, 
which is very broad, and it has many large particles that show high ET deposition. However, 
it could be a relevant particle size for environmental liquid droplets. The term "particulate 
matter" (also known as particle pollution) is a complex mixture including solid particles and 
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liquid droplets found in air. These solid and liquid particles come in a wide range of sizes. 
However, it would be interesting to perform inhalation experiments with airborne particles 
within a narrower range of sizes (i.e., low GSD). All things considered, some limitations can 
be underscored, such as possible errors in AMAD measurements because of liquid particle 
evaporation in transit to and through the ELPI impactor [29]. A cascade impactor can act as a 
warmer to evaporate the particles along the stages, decreasing the particle size and 
increasing the GSD.  
 
Impact of Airborne Particle Size on the Deposition Pattern in Terms of Inhaled Aerosol 
Fraction Deposited in the ET and TH Regions 
 
 The level of injury produced by inhaled toxicants depends on the dose received by 
the lungs and internal organs. Even if a dose expressed in toxicological studies in mg/kg of 
body mass or mg/cm2 of airway surface could not be calculated from these experiments, we 
provided an estimate of the percentage of inhaled material that deposits in the ET and TH 
regions of baboons at resting ventilation for three specific particle size distributions. In this 
sense, we calculated the emitted nebulizer fraction deposited in the ET and TH regions, 
knowing the aerosol amount deposited in each region of the respiratory tract and the emitted 
nebulizer fraction delivered by each nebulizer. We showed that the inhalation exposure to 
[0.25 µm–1 µm] or [0.15 µm–0.5 µm] radioactive aerosol led to the same inhaled fraction 
deposited in the TH region. However, the inhalation exposure to [1 µm–9 µm] or [0.25 µm–1 
µm] radioactive aerosol led to the same inhaled fraction deposited in the ET region (Figure 
3).  
 
Baboon–Human Comparison of In Vivo Experimental Pattern Deposition for the [1 µm–9 µm] 
Airborne Particles 
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Much information concerning inhalation toxicology has been collected from laboratory 
animals as human surrogates in aerosol inhalation studies. The comparative regional 
deposition in these laboratory animals can be considered helpful for interpreting, from a 
dosimetric viewpoint, the possible implications of animal toxicological results for humans. 
The in vivo experiments were conducted with baboons, which were used as a representative 
2-year-old child respiratory tract model. Some studies have indicated that baboons are the 
most predictive primate species for extrapolating aerosol deposition data to humans [30]. 
Total inhaled aerosol deposition probability versus particle size is qualitatively similar for 
various mammals of similar body mass, despite airway anatomy differences, even if more 
species variation can be seen in regional particle deposition curves [31]. However, because 
anatomy and physiology of the respiratory system can significantly differ between species 
(specifically between baboons and children), several parameters must be taken into account 
to evaluate the usefulness of the baboon as an animal model of aerosol delivery in children. 
For example, it is necessary to compare the morphometry of baboon airways with the 
respiratory tract geometry of children. These correlations are critical for subsequent 
extrapolation of aerosol deposition findings in baboons to children. As an example, a large 
database was proposed for developing realistic age-dependent models of the human lung 
from infancy to young adulthood [32]. A morphometric comparison of the nasopharyngeal 
airway of a 3-year-old child and a 10-year-old baboon suggested a functional interspecific 
relationship between the nasal structure, cross-sectional area, and tracheobronchial region 
[15,16]. According to the International Commission on Radiological Protection [33], a 1-year-
old child has a tidal volume of 0.1 L and a minute ventilation of 3.7 L/min (approximately two-
times more than that of the baboons in the study). We assumed the conclusion that the 
breathing parameters (such as the tidal volume) measured in the three studied baboons 
(Table 1) accorded quite well with those of a 1-year-old to 2-year-old child [34]. All things 
considered, the baboon appears to be a satisfactory in vivo respiratory model for a 2-year-old 
child. However, some limitations using baboons as child surrogates can also be 
underscored, such as the intra-animal anatomical variability or the effect of anesthesia on 
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airway muscle tone, which, if airway geometry changed, would significantly affect the aerosol 
amount deposited. 
 
Generally, the number of aerosol particles that reach the pulmonary region in children 
is lower than that in adults [6]. Because of a previous healthy volunteer scintigraphy study 
using the Atomiser NL11 nebulizer, a baboon–adult comparison of in vivo experimental 
pattern deposition for the [1 µm–9 µm] airborne particles can be proposed [35,36]. A similar 
inhalation protocol was used to study the human and baboon deposition patterns, such as 
exposure route, delivery technique used (the same Atomisor NL11 nebulizer having the 
same AMAD and GSD), and definitions of specific respiratory tract regions. The human study 
included seven healthy men aged 21 to 36 years with a mean height of 181 ± 3 cm and a 
mean weight of 77 ± 10 kg who inhaled only via the nose [36].  
 
 The human study showed 73% ± 10% of aerosol deposited in airways was in the ET 
region and 27% ± 10% was in the TH region. Thus, we observed excellent correlation for the 
in vivo regional distribution in terms of total aerosol fraction deposited in human and baboon 
airways (ET region: 73% ± 10% in humans vs. 72% ± 17% in baboons; TH region: 27% ± 
10% in humans vs. 28% ± 17% in baboons). This result led to the conclusion that differences 
in airway architecture or ventilation rate between adult and child respiratory models did not 
have a significant impact on the regional distribution of a [1 µm–9 µm] aerosol in terms of 
total aerosol fraction deposited in the airways with inhalation via the nasal route. This result 
is in good accordance with comparisons of deposition across different age groups performed 
in infants and in adults [11]. An alternative interpretation is that effects of differences in 
airway architecture and ventilation rate between adults and children were compensatory. 
 
Nevertheless, the interspecies differences had a strong impact on the emitted 
nebulizer fraction that was deposited in the ET and TH regions. Based on the healthy 
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volunteer scintigraphy study, if we calculate the emitted nebulizer fraction deposited 
(knowing the aerosol-emitted nebulizer fraction for the Atomiser NL11 nebulizer and the 
deposition fraction expressed as a percentage of the nebulizer charge), we could find an 
emitted nebulizer fraction of 25.2% ± 7% deposited in the ET region and an emitted nebulizer 
fraction of 8.3% ± 3.8% deposited in the TH region. Comparing these results to the baboon 
data (Table 3), we observed a six-fold higher value of emitted nebulizer fraction deposited in 
both the ET and TH regions in humans (ET region: 25.2% ± 7% in humans vs. 3.7% ± 1.6% 
in baboons; TH region: 8.3% ± 3.8% in humans vs. 1.3% ± 0.65% in baboons). We support 
the conclusion that this significant interspecies difference in terms of emitted nebulizer 
fraction deposited is attributable to differences in breathing parameters [37,38]. We 
measured the volume of inspired air at 1.8 ± 0.15 L/min in baboons (Table 1). Because it is 
commonly accepted that the volume of air that can be inspired is approximately 9 L/min in 
humans [33], we found that the volume of inspired air is five-fold higher in humans than in 
baboons (i.e., 9 L vs. 1.8 L). Consequently, this result led us to think that the six-fold higher 
emitted nebulizer fraction deposited in the ET and TH regions in humans compared to 
baboons was mainly attributable to differences in inspired air volume. Thus, our results 
confirm that, for some sizes of airborne particles, regional deposition in humans and baboons 
is quite similar and appears to be species-independent. However, even if these different 
species are exposed to identical particles at an identical concentration, they will not receive 
the same particle mass per unit of exposure time because of their differences in tidal volume 
and breathing rate.  
 
CONCLUSION 
 
Dose and persistence evaluations of inhaled aerosol particles are needed for 
children; data regarding the adult respiratory tract are also lacking, specifically for the 
submicron particle range. Knowledge of the regional distribution of inhaled submicron-size 
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particles in the respiratory tract can help predict the sites of pathological changes attributable 
to airborne nanoparticle agglomerate exposure. Therefore, this study may add new data 
regarding this issue using the baboon animal model as a valuable strategy to assess such 
data.  
 
The size-dependent regionalization of fine and ultrafine aerosol deposition in vivo 
within the baboon respiratory model provides an innovative aspect to this work, mainly 
because previous studies generally focused on determining globally or regionally deposited 
aerosol fractions in adult respiratory models. Results clearly demonstrated that aerosol 
deposition within the TH and ET regions varied substantially according to particle size. A high 
deposition in the ET region was observed for the [1 µm–9 µm] aerosol (72% ± 17%), 
whereas the [0.15 µm–0.5 µm] aerosol was almost exclusively associated with TH deposition 
(84% ± 4%). The [0.25 µm–1 µm] aerosol showed an intermediate deposition pattern, with 
49% ± 8% of deposition in the ET region and 51% ± 8% of deposition in the TH region. 
 
We established that a decrease of the intersubject variability and a targeted 
deposition in the TH region can be achieved by reducing the median activity diameter 
(AMAD) of airborne particles and by enhancing the amount of particles smaller than 0.5 µm. 
For toxicology issues, these results indicate the capacity of 200-nm to 300-nm airborne 
particles to preferentially access the lower airways, which possibly may be associated with a 
systemic translocation through the air–blood barrier of primary nanoparticles because these 
submicron-size structures should be de-agglomerated in body fluids. These data are of value 
not only for risk assessment but also for inhalation therapy strategy evaluation and dosing. 
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TABLE 1. Breathing parameters of the three studied baboons (mean ± standard deviation)  
Breathing rate (breaths/min) 35 ± 7 
Tidal volume (mL) 54 ± 9 
Inspiratory time to expiratory time (I:E) 0.41 ± 0.09 : 0.59 ± 0.09 
Inspired air (L/min) 1.8 ± 0.15 
Age (years) 6.3 ± 0.5 
Weight (kg) 12.3 ± 1.2 
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TABLE 2. Features of the aerosols inhaled by the baboons to assess the impact of particle 
size on the in vivo regional distribution   
Nebulizers 
AMAD (GSD) 
ELPI and 
gamma camera 
Particles 
<2.5 µm 
(FP) 
Particles   
<1 µm 
Particles 
<0.5 µm 
Particles 
<0.1 µm 
(UFP) 
[d16–d84] 
NL11 2.80 µm (3.2) 47.0% ± 
4.3% 
13.6% ± 
1.6% 
4.7% ± 
0.6% 
0.4% ± 
0.05% [1 µm–9 µm]  
Modified 
Sidestream 550 nm (2.1) 
98.6% ± 
0.2% 89.2% ± 2% 
47.9% ± 
4.4% 
1.7% ± 
0.2% [0.25 µm–1 µm] 
Nanoneb 230 nm (1.6) 98.3% ± 0.4% 
97.5% ± 
0.5% 
86.6% ± 
1.8% 
7.3% ± 
1.2% [0.15 µm–0.5 µm] 
 
AMAD, activity median aerodynamic diameter; ELPI, electrical low-pressure impactor; FP, 
fine particle; GSD, geometric standard deviation; UFP, ultrafine particle.  
  
 
 
TABLE 3. Statistical analysis by Bonferroni multiple comparison test: Impact of the airborne 
particle size (i.e., [d16-d84]) on the experimental ET and TH regional depositions 
 
[1 µm–9 µm] 
versus  
[0.25 µm–1 µm] 
[1 µm–9 µm] versus  
[0.15 µm–0.5 µm]  
[0.25 µm–1 µm] 
versus 
[0.15 µm–0.5 µm] 
ET deposition p < 0.001 p < 0.001 p < 0.001 
TH deposition p < 0.001 p < 0.001 p < 0.001 
ET, extrathoracic; TH, thoracic. 
  
  
 
TABLE 4. Impact of airborne particle size on the emitted fraction by each nebulizer and the 
deposition pattern in terms of emitted aerosol fraction deposited in the ET and TH regions  
Nebulizer AMAD (GSD) [d16–d84] Emitted fraction  (%) 
TH deposition  
(% of emitted 
aerosol fraction) 
ET deposition  
(% of emitted 
aerosol fraction) 
NL11 2.80 µm (3.2) [1 µm–9 µm]  44.5 ± 1.5 1.3 ± 0.65 3.7 ± 1.6 
Modified 
Sidestream 550 nm (2.1) [0.25 µm–1 µm] 9.3 ± 3 3.3 ± 0.35 3.45 ± 1.2 
Nanoneb 230 nm (1.6) [0.15 µm–0.5 µm] 4.2 ± 1 3.5 ± 1.6 0.75 ± 0.5 
AMAD, activity median aerodynamic diameter; ET, extrathoracic; GSD, geometric standard 
deviation; TH, thoracic.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
FIG. 1. Activity size distributions of the studied aerosols measured using gamma camera 
detection coupled to the cascade electrical low-pressure impactor. AMAD, activity median 
aerodynamic diameter. 
FIG. 2. In vivo inhalation experiments using baboons. Representative scintigraphic images 
obtained for the three studied aerosols. All images are from the same baboon. Total aerosol 
depositions (%) for the extrathoracic (ET) and thoracic (TH) regions are indicated. Activity 
median aerodynamic diameter (AMAD) and [d16, d84] were noticed for each aerosol generated. 
FIG. 3. In vivo results of aerosol deposition within the extrathoracic (ET) and thoracic (TH) 
regions in terms of the inhaled aerosol fraction (*p < 0.05, **p < 0.01, and ***p < 0.001 by 
Bonferroni multiple comparison test). AMAD, activity median aerodynamic diameter; NS, not 
significant. 
 
 
 
 
 
 
 
 
 
 
  
 
FIGURES 
 
 
FIG. 1. Activity size distributions of the studied aerosols measured using gamma-camera 
detection coupled to the cascade electrical low-pressure impactor. AMAD, activity median 
aerodynamic diameter. 
  
  
 
 
FIG. 2. In vivo inhalation experiments using baboons. Representative scintigraphic images 
obtained for the three studied aerosols. All images are from the same baboon. Total aerosol 
depositions (%) for the extrathoracic (ET) and thoracic (TH) regions are indicated. Activity 
median aerodynamic diameter (AMAD) and [d16, d84] were noticed for each aerosol generated. 
  
  
 
 
FIG. 3. In vivo results of aerosol deposition within the extrathoracic (ET) and thoracic (TH) 
regions in terms of the inhaled aerosol fraction (*p < 0.05, **p < 0.01, and ***p < 0.001 by 
Bonferroni multiple comparison test). AMAD, activity median aerodynamic diameter; ns, not 
significant. 
 
 
 
 
